Glucocorticoid sparing in sarcoidosis using the JAK inhibitor tofacitinib

Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study

(2021) Marcia A. Friedman et al.   LUNG

Challenges of Sarcoidosis and Its Management

(2021) Marjolein Drent et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib for cutaneous and pulmonary sarcoidosis: a case series

(2020) Karolina L. Kerkemeyer et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare

(2019) William Damsky et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis

(2018) William Damsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

IFN-γ–Producing T-Helper 17.1 Cells Are Increased in Sarcoidosis and Are More Prevalent than T-Helper Type 1 Cells

(2016) Joris Ramstein et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE